Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
BexBack Launches $50 Welcome Bonus and 100% Deposit Match to Empower Crypto Traders with 100x Leverage
-
ROSEN, REGARDED INVESTOR COUNSEL, Encourages GoHealth, Inc. Investors to Inquire About Securities Class Action Investigation - GOCO
-
Martini Market Presale Surpasses 40% of Softcap Within 24 Hours of Launch on XRP Ledger
-
Wilson Blanchard Management Raises $169,000 at 2025 WB CondoCon in Support of Associa Cares Canada
-
Wai Lana Re-Releases "Namaste" Music Video for 10th Anniversary of International Yoga Day
-
XRP News: Vaultro Finance Presale on XRP Sells Over 70% of Allocation – Only 30% Now Remaining for Early Investors to Participate
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Semler Scientific, Inc. Investors to Inquire About Securities Class Action Investigation - SMLR
-
AIXA Miner Unveils New Free Cloud Mining Platform Aligned with 2025 Green Tech and Smart Mining Goals
-
QuantaNorth.com reviews how climate policy shifts are affecting commodity prices (by Scott Weber)
-
QuantaNorth.com reviews forex trading strategies for a stronger Canadian dollar environment (by Robert White)
-
Government of Pakistan Recommends President Donald J. Trump for 2026 Nobel Peace Prize
-
WST DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WST
-
‘Reputation House’ Becomes the Only Dubai-Based Winner at the 2025 American Business Awards
-
John Binks Advances Federal Tech Innovation and AI Literacy in Leadership Role at Titan Technologies
-
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medici
-
Bible For Beginners: Themes & Historical Context Practical Guide Released
-
MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session
-
Solytics Partners Appoints Financial Crime Compliance Expert Sunil Kavishwar to Advisory Board to Strengthen AML Efforts in the GCC
-
New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
-
New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
-
Food Hygiene Certificate Launches Nationwide Campaign to Simplify Food Safety Training for UK Workers and Businesses
-
Sid Gandotra Unveils Comprehensive Strategy for Balancing Client Needs and Business Realities to Drive Sustainable Success
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vestis
-
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DoubleVerify
-
GE HealthCare drives innovation in theranostics with latest technological advances
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings
-
SRPT FRAUD NOTICE: Sarepta Therapeutics, Inc. Shareholders that Lost Money are Reminded to Contact BFA Law about the Securities Fraud Investigation
-
RDDT FRAUD NOTICE: Reddit, Inc. Shareholders that Lost Money are Reminded to Contact BFA Law by the August 18 Securities Fraud Class Action Deadline
-
OGN FRAUD NOTICE: Organon & Co. Shareholders that Lost Money are Reminded to Contact BFA Law by the July 22 Securities Fraud Class Action Deadline
-
IOVA FRAUD NOTICE: Iovance Biotherapeutics, Inc. Shareholders that Lost Money are Reminded to Contact BFA Law by the July 14 Securities Fraud Class Action Deadline
-
FTRE FRAUD NOTICE: Fortrea Holdings Inc. Shareholders that Lost Money are Reminded to Contact BFA Law by the August 1 Securities Fraud Class Action Deadline
-
ELV FRAUD NOTICE: Elevance Health, Inc. Shareholders that Lost Money are Reminded to Contact BFA Law by the July 11 Securities Fraud Class Action Deadline
-
CODI FRAUD NOTICE: Compass Diversified Holdings Shareholders that Lost Money are Reminded to Contact BFA Law by the July 8 Securities Fraud Class Action Deadline
-
CIVI FRAUD NOTICE: Civitas Resources, Inc. Shareholders that Lost Money are Reminded to Contact BFA Law by the July 1 Securities Fraud Class Action Deadline
-
DMRC DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Digimarc Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - DMRC
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Open Lending
-
1000 MIGLIA 2025, the fifth and final leg has started
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages DoubleVerify Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DV
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Red Cat Holdings
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Krispy Kreme
-
LWEX Wallet and Token System Launch Simultaneously Opening a New Channel for Ecosystem Development
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Civitas Resources
-
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
-
Understanding Drug Crime Defenses: Why a Nashville Drug Lawyer is Essential
-
Shokz Support 5 Pro Athletes Competing In The 2025 Western States Endurance Run
-
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
